FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020905306> ?p ?o ?g. }

• W2020905306 endingPage "314" @default.
• W2020905306 startingPage "309" @default.
• W2020905306 abstract "Previously, we reported that nondiabetic children with cystic fibrosis show a blunted insulin response to a meal stimulus. In the study presented here, using tolbutamide, we determined the effects of augmented insulin secretion/action on height and lean body mass of children with cystic fibrosis. Twelve subjects (mean ± SEM age, 11.0 ± 0.5 y) were studied for three 4-mo periods: 1) pretreatment, 2) treatment, consisting of 750 mg/d of tolbutamide, and 3) posttreatment. Before the pretreatment period, insulin response to a meal stimulus was evaluated in relation to three doses of tolbutamide: 0, 250, and 500 mg. Growth was monitored during each period, and incremental changes in lean body mass were calculated from height data. To validate the change in lean body mass based on height measurements, we determined lean body mass in seven subjects during the treatment period by using a criterion method (H218O). Growth velocity (cm/4 mo) significantly increased (p < 0.05) during the treatment (2.58 ± 0.31) compared with the pretreatment period (0.88 ± 0.20). The increase in lean body mass calculated from height was greater during the treatment (1.61 ± 0.29 kg/4 mo) than during the pretreatment period (0.44 ± 0.18 kg/4 mo) (p < 0.05). There was also a significant increase (p < 0.05) in lean body mass during the treatment as measured with H218O (1.91 ± 0.65 kg/4 mo). Acute administration of either 250 or 500 mg of tolbutamide reduced (p < 0.05) the area under the glucose concentration curve in response to a meal compared with the control condition of no tolbutamide. However, there was no significant effect of tolbutamide on plasma insulin levels. We conclude that short-term tolbutamide therapy more than doubled linear growth and increased lean body mass accretion 4-fold in slowly growing children with cystic fibrosis, possibly by improving the tissue response to insulin. (Pediatr Res 30: 309–314, 1991)" @default.
• W2020905306 created "2016-06-24" @default.
• W2020905306 creator A5027828012 @default.
• W2020905306 creator A5048179026 @default.
• W2020905306 creator A5054917852 @default.
• W2020905306 creator A5059942174 @default.
• W2020905306 creator A5060008926 @default.
• W2020905306 creator A5062124660 @default.
• W2020905306 date "1991-10-01" @default.
• W2020905306 modified "2023-09-27" @default.
• W2020905306 title "Effects of Tolbutamide on Growth and Body Composition of Nondiabetic Children with Cystic Fibrosis" @default.
• W2020905306 cites W2007492183 @default.
• W2020905306 cites W2188643303 @default.
• W2020905306 cites W2423271602 @default.
• W2020905306 doi "https://doi.org/10.1203/00006450-199110000-00004" @default.
• W2020905306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1956712" @default.
• W2020905306 hasPublicationYear "1991" @default.
• W2020905306 type Work @default.
• W2020905306 sameAs 2020905306 @default.
• W2020905306 citedByCount "32" @default.
• W2020905306 countsByYear W20209053062022 @default.
• W2020905306 crossrefType "journal-article" @default.
• W2020905306 hasAuthorship W2020905306A5027828012 @default.
• W2020905306 hasAuthorship W2020905306A5048179026 @default.
• W2020905306 hasAuthorship W2020905306A5054917852 @default.
• W2020905306 hasAuthorship W2020905306A5059942174 @default.
• W2020905306 hasAuthorship W2020905306A5060008926 @default.
• W2020905306 hasAuthorship W2020905306A5062124660 @default.
• W2020905306 hasBestOaLocation W20209053061 @default.
• W2020905306 hasConcept C120863210 @default.
• W2020905306 hasConcept C126322002 @default.
• W2020905306 hasConcept C134018914 @default.
• W2020905306 hasConcept C140793950 @default.
• W2020905306 hasConcept C147583825 @default.
• W2020905306 hasConcept C185592680 @default.
• W2020905306 hasConcept C2776054734 @default.
• W2020905306 hasConcept C2776938444 @default.
• W2020905306 hasConcept C2778345441 @default.
• W2020905306 hasConcept C2779306644 @default.
• W2020905306 hasConcept C71924100 @default.
• W2020905306 hasConcept C86803240 @default.
• W2020905306 hasConceptScore W2020905306C120863210 @default.
• W2020905306 hasConceptScore W2020905306C126322002 @default.
• W2020905306 hasConceptScore W2020905306C134018914 @default.
• W2020905306 hasConceptScore W2020905306C140793950 @default.
• W2020905306 hasConceptScore W2020905306C147583825 @default.
• W2020905306 hasConceptScore W2020905306C185592680 @default.
• W2020905306 hasConceptScore W2020905306C2776054734 @default.
• W2020905306 hasConceptScore W2020905306C2776938444 @default.
• W2020905306 hasConceptScore W2020905306C2778345441 @default.
• W2020905306 hasConceptScore W2020905306C2779306644 @default.
• W2020905306 hasConceptScore W2020905306C71924100 @default.
• W2020905306 hasConceptScore W2020905306C86803240 @default.
• W2020905306 hasIssue "4" @default.
• W2020905306 hasLocation W20209053061 @default.
• W2020905306 hasLocation W20209053062 @default.
• W2020905306 hasOpenAccess W2020905306 @default.
• W2020905306 hasPrimaryLocation W20209053061 @default.
• W2020905306 hasRelatedWork W1971958409 @default.
• W2020905306 hasRelatedWork W2068108356 @default.
• W2020905306 hasRelatedWork W2071138625 @default.
• W2020905306 hasRelatedWork W2083606604 @default.
• W2020905306 hasRelatedWork W2090215252 @default.
• W2020905306 hasRelatedWork W2102284920 @default.
• W2020905306 hasRelatedWork W2141993464 @default.
• W2020905306 hasRelatedWork W2144753412 @default.
• W2020905306 hasRelatedWork W2410507625 @default.
• W2020905306 hasRelatedWork W4254115420 @default.
• W2020905306 hasVolume "30" @default.
• W2020905306 isParatext "false" @default.
• W2020905306 isRetracted "false" @default.
• W2020905306 magId "2020905306" @default.
• W2020905306 workType "article" @default.